Increased risk for severe infections

Up in smoke: Smoking increases SARS-CoV-2 receptors in the lung

New research suggests that cigarette smoke spurs the lungs to make more ACE2 (angiotensin-converting enzyme 2), the protein that the coronavirus responsible for COVID-19 grabs and uses to enter human cells.

The findings, reported in the journal Developmental Cell, may explain why smokers appear to be particularly vulnerable to severe infections. The analysis also indicates that the change is reversible, suggesting that quitting smoking might reduce the risk of a severe coronavirus infection.

coronavirus in cigarette smoke

Image source: CDC/ Alissa Eckert, MS; Dan Higgins, MAM / Unsplash/Damon Lam (mashup: HiE)

From the early stages of the current pandemic, scientists and clinicians have noted dramatic differences in how people respond to infection with SARS-CoV-2. Most infected individuals suffer only mild illness, if they experience any at all. But others require intensive care when the sometimes-fatal virus attacks. Three groups, in particular, have been significantly more likely than others to develop severe illness: men, the elderly, and smokers. 

With most laboratory experiments on hold due to the pandemic, Cold Spring Harbor Laboratory (CSHL) Fellow Jason Sheltzer and Joan Smith, an engineer at Google, turned to previously published data to seek possible explanations for these disparities. They were curious whether the vulnerable groups might share some key feature related to the human proteins that the coronavirus relies on for infection. “We started gathering all the data we could find,” Sheltzer says, explaining that he and Smith focused first on comparing gene activity in the lungs across different ages, between the sexes, and between smokers and nonsmokers. “When we put it all together and started analyzing it, we saw that both mice that had been exposed to smoke in a laboratory and humans who were current smokers had significant upregulation of ACE2.”

Recommended article

Photo

Coronavirus disease research

Seeking a COVID-19 antidote: the potential of ACE2

As coronavirus disease COVID-19 continues to jet and alight invisibly around the globe, scientists now report that the virus has mutated to become two strains: the older ‘S-type’ appears milder and less infectious, while the later-emerging ‘L-type’, is more aggressive, spreads more quickly, and currently accounts for about 70 per cent of cases. Worldwide, medical researchers are exploring…

While they found no evidence that age or sex impacts ACE2 levels in the lungs, the influence of smoke exposure was surprisingly strong, Sheltzer says. The change appears to be temporary, however: the data revealed that the level of ACE2 in the lungs of people who had quit smoking was similar to that of non-smokers. Sheltzer, Smith, and colleagues also found that the most prolific producers of ACE2 in the airways are mucus-producing cells called goblet cells. Smoking is known to increase the prevalence of such cells, a change that can protect the airways from irritants but—by amplifying the amount of ACE2 in the lungs—may also increase vulnerability to SARS-CoV-2.


Source: Cold Spring Harbor Laboratory (CSHL)

08.06.2020

Read all latest stories

Related articles

Photo

Immunological memory

How our lungs 'remember' a Covid-19 infection

After infection with SARS-CoV-2, where does the immune system store the memory to provide long-term protection against reinfection? Though numerous studies have examined blood to track immune…

Photo

Respiratory research

Covid-19 infection does not affect lung function in kids, young adults

Covid-19 infection does not appear to affect the lung function of young adults, according to new research presented at the ‘virtual’ European Respiratory Society International Congress. In the…

Photo

Coronavirus medication research

Lab-grown beating heart cells could identify Covid drugs

Scientists have grown beating heart cells to attempt to identify drugs to prevent Covid-19-related heart damage. Concerns over the extent of cardiac damage among Covid patients emerged during the…

Related products

Beckman Coulter – Access Interleukin-6 (IL-6)

Immunoassays

Beckman Coulter – Access Interleukin-6 (IL-6)

Beckman Coulter, Inc.
Beckman Coulter – SARS-CoV-2 Assays

Immunoassays

Beckman Coulter – SARS-CoV-2 Assays

Beckman Coulter, Inc.
FUJIFILM Wako - Autokit CH50 Assay

Clinical Chemistry

FUJIFILM Wako - Autokit CH50 Assay

Wako Chemicals GmbH
Green Spring – COVID-19 IgG/IgM Antibody Rapid Test Kit

Green Spring – COVID-19 IgG/IgM Antibody Rapid Test Kit

Shenzhen Lvshiyuan Biotechnology Co.,Ltd
Subscribe to Newsletter